Healthcare Value Trap Risk: AMGN, MRK Face Momentum Fade

The June healthcare sector dashboard from Seeking Alpha lays out a split picture. Value metrics look cheap. Momentum is not cooperating. For holders of Amgen (AMGN) and Merck (MRK), the tension matters more than the sector average.

AMGN scores 54 out of 100 on AlphaScala's composite measure. The label is "Mixed." Quality is decent. Momentum is weak. The biotech giant's forward P/E has compressed as pipeline catalysts stalled. The dividend yield offers a floor. MRK lands at 49, also "Mixed." Its oncology franchise generates cash. The Keytruda patent cliff in 2028 hangs over the valuation. Neither stock screams value trap. Neither is a momentum leader.

The dashboard's value factor favors the sector overall. Healthcare trades at a discount to its own five-year average on price-to-book and price-to-sales. That is the simple read. The better read is that the discount exists because earnings estimates have been sliding. Revenue growth for the median healthcare stock has decelerated for three straight quarters. Cheapness without earnings momentum is a value trap.

Quality metrics tell a different story. Return on equity and debt-to-capital ratios remain above the market median. That is the simple read. The better read is that quality is already priced in. The sector's quality premium has narrowed. Investors are not getting paid extra for owning high-ROE names. AMGN and MRK both carry strong balance sheets. The market is not rewarding them for it right now.

Momentum is the weak link. The healthcare sector's six-month price return trails the S&P 500 by roughly 400 basis points. Large-cap pharma has been the laggard within the sector. AMGN is down about 8% year-to-date. MRK is roughly flat. The dashboard's momentum percentile for the sector sits in the bottom quartile. That is a risk for anyone adding exposure here. Momentum tends to persist. A sector that is already out of favor rarely reverses without a catalyst.

The next catalyst for AMGN is the July 31 earnings report. Investors will look for updates on the MariTide obesity drug. For MRK, the focus is on the Gardasil franchise and any signs of China demand recovery. Neither event is binary enough to shift the sector's trajectory alone. The broader risk is that healthcare continues to underperform as money rotates into tech and industrials.

What would confirm the bearish case for the sector? A second straight quarter of earnings estimate cuts across the group. What would weaken it? A surprise approval or positive trial readout that resets sentiment. Right now, the data leans toward caution. The dashboard's composite score for healthcare is below the market median. The trend is not improving.

The sector offers a valuation cushion but no momentum tailwind. That makes it a hold, not a buy, until either earnings stabilize or a stock-specific catalyst emerges. AMGN and MRK are the two names to watch for that signal, given their weight in IXJ and their exposure to the patent and pipeline narratives.

The dashboard updates monthly. The next print will show whether June's value discount was a buying opportunity or a value trap. That answer depends on July's earnings season.